Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook – CNBC
Lead On Feb. 3, 2026, Pfizer reported fourth-quarter results that topped Wall Street estimates even as demand for its Covid vaccine and antiviral Paxlovid continued to fall. The company posted adjusted earnings per share of $0.66 and revenue of $17.56 billion, beating consensus. Management reiterated a conservative 2026 outlook and highlighted longer-term investments, including the … Read more